The Most Detailed Look Yet at What Cannabis Smoking Does to the Lungs

Cross-sectional study of 139 cannabis smokers and 57 never-smokers. Multi-modal assessment: respiratory symptom questionnaires, spirometry, chest CT, hyperpolarized xenon-129 MRI, bronchoscopic airway epithelial brushings with transcriptomic analysis, and air-liquid interface cell cultures for MUC5AC protein quantification.

This is one of the most methodologically comprehensive studies of cannabis smoking's respiratory effects. Most prior research relied on questionnaires and basic spirometry. By adding advanced imaging (xenon MRI), cellular analysis (bronchoscopic brushings), and molecular data (gene expression, protein quantification), the CANUCK study provides multiple converging lines of evidence that cannabis smoking affects the airways at structural, functional, and molecular levels.

The respiratory effects of cannabis smoking have been studied less rigorously than tobacco, partly because cannabis was illegal in most research settings until recently. Canada's 2018 legalization enabled studies like CANUCK. The finding that mucin gene upregulation and MUC5AC overproduction occur in cannabis smokers echoes pathways well-established in tobacco-related COPD — raising the question of whether heavy cannabis smoking could follow a similar trajectory to chronic lung disease. The smoking-versus-vaping comparison (RTHC-00231) and the cardiovascular data (RTHC-00237) add additional dimensions to the inhalation risk picture.

Cross-sectional design cannot establish causation or track progression over time. The 84% tobacco/vaping co-use rate makes it difficult to attribute findings specifically to cannabis. Participants were relatively young (median 27), so long-term consequences may not yet be manifest. The study recruited from a single Canadian center, limiting generalizability.